A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor

被引:116
作者
Chang, LCW [1 ]
Künzel, JKVF [1 ]
Mulder-Krieger, T [1 ]
Spanjersberg, RF [1 ]
Roerink, SF [1 ]
van den Hout, G [1 ]
Beukers, MW [1 ]
Brussee, J [1 ]
IJzerman, AP [1 ]
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-2300 RA Leiden, Netherlands
关键词
D O I
10.1021/jm049597+
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Adenosine receptor agonists are usually variations of the natural ligand, adenosine. The ribose moiety in the ligand has previously been shown to be of great importance for the agonistic effects of the compound. In this paper, we present a series of nonadenosine ligands selective for the adenosine A(1) receptor with an extraordinary pharmacological profile. 2-Amino-4-benzo[1,3]dioxol-5-yl-6-(2-hydroxyethylsulfanyl)pyridine-3,5-dicarbonitrile (70, LUF 5853) shows full agonistic behavior comparable with the reference compound CPA, while also displaying comparable receptor binding affinity (K-i = 11 nM). In contrast, compound 58 (2-amino-4-(3-trifluoromethylphenyl)-6-(2-hydroxyethylsulfanyl)pyridine-3,5-dicarbonitrile, LUF 5948) has a binding affinity of 14 nM and acts as an inverse agonist. Also present within this same series are compounds that show neutral antagonism of the adenosine A(1) receptor, for example compound 65 (2-amino-4-(4-difluoromethoxyphenyl)-6-(2-hydroxyethylsulfanyl)pyridine-3,5-dicarbonitrile, LUF 5826).
引用
收藏
页码:2045 / 2053
页数:9
相关论文
共 20 条
[1]
Mapping the binding site pocket of the serotonin 5-hydroxytryptamine(2A) receptor - Ser(3.36(159)) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin [J].
Almaula, N ;
Ebersole, BJ ;
Zhang, DQ ;
Weinstein, H ;
Sealfon, SC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (25) :14672-14675
[2]
[Anonymous], UNPUB
[3]
New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist n-ethylcarboxamidoadenosine [J].
Beukers, MW ;
Chang, LCW ;
Künzel, JKVD ;
Mulder-Krieger, T ;
Spanjersberg, RF ;
Brussee, J ;
Ijzerman, AP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (15) :3707-3709
[4]
BRUNS RF, 1980, CAN J PHYSIOL PHARM, V58, P673, DOI 10.1139/y80-110
[5]
Synthesis and biological evaluation of disubstituted N6-cyclopentyladenine analogues:: the search for a neutral antagonist with high affinity for the adenosine A1 receptor [J].
de Ligt, RAF ;
van der Klein, PAM ;
Künzel, JKVD ;
Lorenzen, A ;
El Maate, FA ;
Fujikawa, S ;
van Westhoven, R ;
van den Hoven, T ;
Brussee, J ;
IJzerman, AP .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (01) :139-149
[6]
Molecular basis of partial agonism: Orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy [J].
Ebersole, BJ ;
Visiers, I ;
Weinstein, H ;
Sealfon, SC .
MOLECULAR PHARMACOLOGY, 2003, 63 (01) :36-43
[7]
Fredholm BB, 2001, PHARMACOL REV, V53, P527
[8]
Recent advances in adenosine receptor antagonist research [J].
Hess, S .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (10) :1533-1561
[9]
KAMBE S, 1981, SYNTHESIS-STUTTGART, P531
[10]
Klotz KN, 1998, N-S ARCH PHARMACOL, V357, P1